Summary of GE HealthCare Technologies Conference Call Company Overview - **Company**: GE HealthCare Technologies (NasdaqGS:GEHC) - **Event**: 2025 Conference at Jefferies Global HealthCare Conference - **Key Speakers**: Jay Saccaro (CFO), Carolynne Borders (Investor Relations) Core Industry Insights - **Healthcare Mission**: GE HealthCare aims to create a world where healthcare has no limits, focusing on innovation and growth across its business segments [2][3] - **Business Segments**: The company operates in four segments, with a strong emphasis on imaging, ultrasound, and surgical products [3][4] Financial Performance - **Sales Growth**: The AVS (ultrasound and surgical) business grew by 6% in Q3, indicating strong innovation and product refreshment [4] - **Order Growth**: The company reported a 6% growth in orders, with a near-record backlog and a book-to-bill ratio of 1.06 [7][11] - **Revenue Growth Goals**: GE HealthCare aims for mid-single digit growth (4%-6%) over the next several years, with expectations of acceleration in 2026 [12][15] Market Dynamics - **CapEx Environment**: The capital expenditure environment is described as robust, with strong interest in radiology equipment across various markets, including the U.S., EMEA, and China [6][10] - **Challenges in China**: The Chinese market has been challenging, but there are signs of recovery and increased tender activity [9][10] Margin and Cost Management - **Margin Expansion**: The company targets a margin of 17%-20% in the midterm, with a focus on revenue growth, margin expansion, and free cash flow conversion [18][20] - **Tariff Impact**: In 2025, GE HealthCare faced a tariff impact of approximately $260 million, but expects to reduce this in the following year due to improved supply chain strategies [19][21] Product Innovation - **New Product Launches**: Upcoming product launches at RSNA include advancements in photon counting and next-generation MR devices, expected to drive sales growth in 2027 [14][15] - **AI Integration**: The company has 100 FDA-approved AI modules, enhancing imaging quality and efficiency, with significant traction in products like Air Recon DL [35][37] Strategic Initiatives - **Flyrcado Product**: The Flyrcado product is positioned as a game changer in myocardial perfusion imaging, with partnerships and pilot studies indicating strong demand [26][27] - **Contrast Agents Market**: Despite new generic entrants, GE HealthCare expects to maintain its market position due to its consistency of supply and broad product portfolio [30][33] Conclusion - **Outlook**: GE HealthCare is optimistic about future growth driven by innovation, a strong product pipeline, and strategic partnerships, while managing challenges in tariffs and market dynamics effectively [28][29]

Financial Performance - Organic revenue grew 4% year-over-year, with total revenues of $5.1 billion [9][10] - Adjusted EPS was $1.07, down 6% year-over-year, impacted by approximately $0.16 from tariffs [10][18] - Free cash flow was $483 million, down $168 million year-over-year, primarily due to higher receivables and tariff payments [17] Business Segment Performance - Imaging segment organic revenue increased by 4%, with EBIT margin declining by 260 basis points due to tariff pressures [12] - Advanced Visualization Solutions (AVS) saw organic revenue growth of 6% and EBIT margin increased by 180 basis points [13] - Patient Care Solutions (PCS) experienced a 7% decline in organic revenue due to a product hold, with EBIT margin down 680 basis points [15] - Pharmaceutical Diagnostics (PDx) reported a strong quarter with 10% organic revenue growth, although EBIT margin declined by 150 basis points due to planned investments [16] Market Performance - Strong growth observed in EMEA and the U.S. markets, with robust orders growth of 6% across all segments [4][9] - The company is optimistic about the recovery in the Chinese market, with improvements in tender activity [28][29] Company Strategy and Industry Competition - The company is focused on executing its precision care strategy and has invested over $3 billion in R&D since 2022 [20] - A 14-year care alliance with UC San Diego Health was announced, emphasizing the company's commitment to innovative solutions in cancer care [5] - The planned acquisition of icometrix aims to enhance capabilities in Alzheimer's care, showcasing the company's strategy to integrate digital tools into its offerings [7] Management Commentary on Operating Environment and Future Outlook - Management raised adjusted EPS guidance for the full year, reflecting strong performance and healthy capital investment trends [18] - The company expects to deliver free cash flow of at least $1.4 billion for the full year, despite tariff impacts [18] - Management remains confident in achieving mid-single-digit organic growth in the medium term, supported by ongoing innovation and product launches [31][32] Other Important Information - The company has mitigated approximately 50% of its 2025 gross tariff exposure and aims for a lower net tariff impact in 2026 [8] - The company is preparing to introduce a significant number of new AI-powered products at the upcoming RSNA conference [24] Q&A Session Summary Question: Update on growth in China - Management noted improvements in tender activity and expressed optimism about the long-term potential of the Chinese market [28][29] Question: Revenue growth acceleration and targets - Management confirmed confidence in achieving mid-single-digit organic growth, with expectations that China’s stability will support this goal [30][31] Question: Performance in Q3 and guidance for Q4 - Management reiterated full-year revenue guidance, expecting 3%-4% growth in Q4, with a recovery in PCS contributing to this [37] Question: Flyrcado product ramp-up - Management indicated a slower ramp in 2025 due to prioritizing customer experience, with expectations for significant growth in 2026 and beyond [40][42] Question: Photon counting technology update - Management confirmed plans are on track for photon counting technology, with more details expected at the upcoming RSNA [48][49] Question: Patient Care Solutions performance - Management acknowledged the decline in PCS due to a product hold but expressed confidence in recovery and future growth under new leadership [50][51] Question: Opportunities in electrophysiology - Management highlighted the potential in electrophysiology, particularly in the ASC setting, and emphasized their competitive positioning [56][57]

Core Insights - Hologic (HOLX) anticipates a return to mid-single-digit organic revenue growth in 2026, driven by a recovery in its Breast Health business [1][8] - The company has restructured its sales teams to enhance focus on capital and disposable product segments, which is expected to improve performance [2][8] - Hologic is launching innovative products, including Genius AI Detection PRO and the next-generation Envision gantry, aimed at improving imaging capabilities and operational efficiency [4][8] Financial Performance - In the third quarter, Hologic's Breast Health revenues declined compared to the previous year but showed sequential improvement, slightly exceeding company expectations [1] - Interventional organic sales grew by 6% in the third quarter, with reported sales increasing by 31.8%, aided by the contribution from Endomagnetics [3] - Hologic's stock has increased by 7.4% over the past six months, contrasting with a 14.9% decline in the industry [7] Competitive Landscape - GE Healthcare reported strong revenue growth across all segments, with adjusted EPS rising to 93 cents from 13 cents year-over-year, driven by demand for radiopharmaceutical products [5] - Merit Medical Systems exceeded financial expectations in the second quarter, achieving a record operating margin of 21.2% [6] Valuation Metrics - Hologic is currently trading at a forward three-year price-to-earnings ratio of 15.28X, which is below the industry average of 28.00X [9] - Analyst estimates for Hologic's EPS show a mixed trend for fiscal years 2025 and 2026, with current estimates at 4.22 for 2025 and 4.48 for 2026 [10][11]

Core Insights - GE HealthCare Technologies Inc. (GEHC) is set to report its second-quarter 2025 results on July 30, with a history of earnings surprises, averaging 8.92% over the last four quarters [1][2] Q2 Estimates - The Zacks Consensus Estimate for revenues is $4.97 billion, indicating a year-over-year growth of 2.8% [2] - The estimated earnings per share (EPS) is $0.91, reflecting a decline of 9% compared to the previous year [2] Segmental Overview - The Imaging segment is crucial for revenue and margin growth, achieving 5% organic revenue growth in Q1, primarily in the U.S., with a 130-basis point EBIT margin expansion [3] - Advanced Visualization Solutions (AVS) reported 3% organic revenue growth in Q1, driven by the U.S. market, with a slight EBIT margin increase of 10 basis points [4] - Patient Care Solutions (PCS) saw 2% organic growth in Q1, but EBIT margin declined by 450 basis points due to tariffs and unfavorable product mix [5] - Pharmaceutical Diagnostics (PDx) excelled with 8% organic revenue growth and maintained an EBIT margin above 32%, bolstered by increased procedure volumes and positive pricing dynamics [6] Other Factors to Note - Tariffs are a significant concern, with an expected adjusted EPS drag of approximately $0.85 for the full year and nearly $100 million impact anticipated in Q2 [7][8] - The company has implemented mitigation strategies but expects ongoing challenges from high-cost inventory [8] - Innovation is a key focus, with the launch of Flyrcado and plans for regulatory submission of a photon-counting CT system later this year [9]

Core Insights - GE HealthCare (GEHC) introduced Flyrcado, an FDA-approved PET imaging agent for myocardial perfusion imaging, at the 2025 SNMMI annual meeting, highlighting its importance in precision cardiac care as cardiovascular disease rates rise globally [1][8] - Flyrcado aims to enhance early disease detection, personalize treatment strategies, and monitor therapy responses, reinforcing GEHC's commitment to improving outcomes for patients at risk of cardiovascular disease [2][6] Product Details - Flyrcado (flurpiridaz F 18) is designed for patients with known or suspected coronary artery disease, featuring a half-life of approximately 110 minutes, which facilitates centralized production and distribution [3] - The agent integrates exercise stress testing with cardiac PET imaging and is compatible with GEHC's Omni Legend PET/CT and other systems, enabling detailed assessments of myocardial perfusion and related conditions [3] Market Position and Coverage - Flyrcado has recently launched in select U.S. markets, receiving CMS pass-through status and a specific HCPCS billing code, with coverage from all seven Medicare Administrative Contractors and over 50% of commercial insurers [4][8] - The expansion of coverage beyond hospital outpatient settings and the establishment of a Flyrcado Support Center for providers indicate a strategic move to enhance accessibility and support for the new imaging agent [4] Financial Performance and Stock Trends - Following the announcement, GEHC shares closed flat at $71.16, with a year-to-date decline of 9%, contrasting with the industry's 4% growth and the S&P 500's 0.8% increase [5][7] - GEHC's market capitalization stands at $32.64 billion, and the company reported a 10.9% earnings surprise in the last quarter, indicating potential for future growth despite current stock performance [7] Strategic Implications - Flyrcado positions GEHC for long-term growth in the high-value molecular imaging market, addressing the rising demand for precision cardiac diagnostics [6] - With broad payer coverage and compatibility with existing systems, Flyrcado is expected to facilitate a shift from SPECT to PET imaging, generating recurring revenue from both radiopharmaceutical sales and imaging hardware [6]

Investment Rating - The industry investment rating is Attractive [6]. Core Insights - A new study in Italy indicates that Surgical Aortic Valve Replacement (SAVR) may have better mortality outcomes compared to Transcatheter Aortic Valve Replacement (TAVR) in younger patients with intermediate surgical risk, showing all-cause mortality rates of approximately 47.2% for TAVR versus 24.6% for SAVR in Lombardy, and 44.1% versus 18.1% in Puglia [1][4]. - The study involved around 7,000 patients and suggests that recent advancements in SAVR techniques may contribute to these findings, contrasting with previous sponsor studies [1]. - In the kidney transplant sector, data from the European Renal Association suggests that less stringent donor criteria do not necessarily correlate with improved survival outcomes, particularly as recipient age increases [4]. - The demand for kidney transplants is rising, with over 60,000 adults currently on the waitlist, which may lead to broader acceptance criteria by transplant centers [4]. - SS Innovations International performed the first fully-robotic cardiac surgery in the Americas, indicating a growing trend in robotic-assisted surgeries [9]. - GE HealthCare Technologies' Flyrcado software has been shown to enhance throughput for cardiac imaging, presenting a significant market opportunity estimated at around $500 million [10]. Summary by Sections Surgical Aortic Valve Replacement (SAVR) vs. Transcatheter Aortic Valve Replacement (TAVR) - The study highlights a significant difference in mortality rates favoring SAVR over TAVR in younger patients [1][4]. - The findings challenge previous clinical trial results and suggest that advancements in surgical techniques may be influencing outcomes [1]. Kidney Transplantation - The European Renal Association's findings indicate that broader donor criteria may not lead to better survival rates, especially in older recipients [4]. - The increasing number of patients on the kidney waitlist is pushing centers to reconsider donor acceptance criteria [4]. Robotic Surgery and Imaging Technology - The first fully-robotic cardiac surgery in the Americas marks a milestone for robotic surgical technology [9]. - The introduction of Flyrcado software by GE HealthCare Technologies is expected to significantly improve cardiac imaging efficiency, with a notable market potential [10].